A Cost Analysis of Alprostadil in Liver Transplantation
Alprostadil (prostaglandin Ei) administration to liver transplant recipients has been shown to result in a significant reduction in the duration of hospital admission for transplantation, and in the need for re-operations (other than re-transplants) and renal support. To study the economic impact of this finding, we examined data from a controlled trial for all single-transplant surviving patients (42 alprostadil, 49 controls) for whom complete billing records were available for transplant days -2 to +150. All costs were measured in 1992 US dollars.
Patients given alprostadil had lower total charges [mean ± standard deviation (SD) $US175 297 ± $US70 652] than patients given placebo (mean ± SD $US225 672 ± $US187 208) [p = 0.043]. The data suggest that the use of alprostadil may have a significant favourable impact on the cost of liver transplantation.
KeywordsLiver Transplantation Adis International Limited Orthotopic Liver Transplantation Professional Service Liver Transplant Recipient
Unable to display preview. Download preview PDF.
- 1.American Hospital Association (AHA). Transplants — 1993. AHA News 1994 Jul 4; 30: 2Google Scholar
- 2.Hockerstedt K. Liver transplantation: a changing concept. Trans Proc 1994; 26: 1706–1707Google Scholar
- 5.Kania AJ. Market memo: transplant study supports centers of excellence. Health Care Strateg Manag 1993; 11: 18–23Google Scholar
- 6.Pageaux GP, Souche B, Perney P, et al. Results and cost of orthotopic liver transplantation for alcoholic cirrhosis. Trans Proc 1993; 25: 1135–1136Google Scholar
- 10.Staschak S, Wagner S, Block G, et al. A cost comparison of liver transplantation with FK506 or CyA as the primary immunosuppressive agent. Trans Proc 1990; 22: 47–49Google Scholar
- 11.Tancharoen S, Jones RM, Agnus PW, et al. Beneficial effect of prostaglandin Ei on hepatic allograft rejection following orthotopic liver transplantation. Trans Proc 1993; 25: 2890–2891Google Scholar
- 14.Takaya S, Bronsther O, Abu-Elmagd K. Use of prostaglandin Ei in crossmatch-negative liver transplant recipients treated with FK506. Trans Proc 1993; 25: 2381–2385Google Scholar
- 17.Merion RM, Bockenstedt PL, McLaren ID, et al. Mechanism of action of prostaglandin Ei in liver transplantation (OLT) [abstract]. Meetings of the American Gastroenterologic Association and the American Association for the Study of Liver Diseases at Digestive Disease Week; 1995; San DiegoGoogle Scholar
- 18.Finkler SA. The distinction between costs and charges. Ann Intern Med 1982; 96: 101–109Google Scholar
- 19.Takaya S, Doyle H, Todo S, et al. Reduction of primary non-function with prostaglandin Ei after clinical liver transplantation. Trans Proc 1995; 27: 1862–1867Google Scholar